Nuclear Matrix Protein Number 22 (NMP 22) indicates the activities of cells pertaining to their mitotic division. It acts as a tumour marker for the detection of bladder cancer. NMP 22 is a method of cancer detection approved by the FDA and CE. It is known as “NMP 22 bladder check” on commercial grounds. The process is convenient and quick because results can be obtained within the first 30 minutes of the test. The process is a collaboration of diagnosis, screening and treatment of bladder cancer by undertaking the necessary precautions along with uniform diagnostic procedures.